Goldman Sachs initiated coverage of ResMed (RMD) with a Buy rating and A$48.90 price target The firm says its Buy thesis is based on “robust” ...
Eli Lilly (LLY) reduced its fourth-quarter sales guidance by 5%, lowering expectations to $13.5 billion. This figure is $400 ...
A Bucks County woman is speaking out after her insurance company decided to no longer cover weight loss drugs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback